← Innovent Biologics Inc/ADR (IVBXF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Innovent Biologics Inc/ADR (IVBXF)
Biotechnology · market cap $24.9B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
7
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Innovent Biologics (IVBXF) is a Chinese biotechnology company with ~6,190 employees and a market cap of approximately $19.2B, trading near $10.30/ADR. The company operates a broad pipeline spanning oncology, immunology, metabolic disease, and ophthalmology, anchored by a Phase 3 picankibart program in plaque psoriasis and multiple near-term catalysts in diabetes (IBI362), hypercholesterolemia (IBI306), and solid tumors. The next 6 months are dense with Phase 2 and Phase 3 readouts, making the second half of 2026 a pivotal period for the story.
The catalyst path
- 2026-10-31 (est.)Phase 2 · IBI3003imp 7/10
- 2026-12-30 (est.)Phase 3 · Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）imp 9/10
- 2026-12-31 (est.)Phase 2 · IBI302imp 7/10
- 2027-03-23 (est.)Phase 2 · IBI3002imp 7/10
- 2027-04-30 (est.)Phase 3 · Febuxostatimp 9/10
- 2027-05-07 (est.)Phase 3 · IBI362imp 9/10
- 2027-06-30 (est.)Phase 3 · IBI343imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Picankibart | Phase 3 | Plaque Psoriasis |
| Febuxostat | Phase 3 | Gout |
| IBI311 (20 mg) | Phase 2 | Thyroid Eye Disease |
| Low dose IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration |
| IBI3003 | Phase 2 | Multiple Myeloma |
| IBI112 dose 2 | Phase 2 | Psoriasis |
| PD1 | Phase 2 | Relapsed/Refractory Classical Hodgkin's Lymphoma |
| IBI301 plus CHOP | Phase 3 | Diffuse, Large B-Cell, Lymphoma |
| IBI376 | Phase 2 | Indolent Non-hodgkin Lymphoma |
| IBI311 | Phase 3 | Thyroid Eye Disease |
| IBI363 | Phase 2 | Melanoma |
| IBI310 | Phase 3 | Advanced Cervical Cancer |
| IBI334 | Phase 2 | Advanced Solid Tumors |
| IBI130 | Phase 2 | Solid Tumor |
| IBI354 | Phase 3 | Locally Advanced Unresectable or Metastatic Solid Tumors |
| IBI129 | Phase 2 | Solid Tumor |
| IBI308 | Phase 3 | Esophageal Squamous Cell Carcinoma |
| IBI343,sintilimab,oxaliplatin,S-1 | Phase 2 | CLDN18.2 Positive |
| IBI112 | Phase 3 | Psoriasis |
| IBI302 8mg dose | Phase 2 | Neovascular Age-related Macular Degeneration |
Price & technical context
3-month
+13.1%
6-month
+6.9%
12-month
+2.1%
52-wk range
$9.10–$15.01
vs 50-day MA
+0.3%
vs 200-day MA
+12.4%
Realized vol
78.9%
Max drawdown
-38.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IVBXF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.